These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16630097)

  • 1. Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lower-extremity ulcers.
    Cavorsi J; Vicari F; Wirthlin DJ; Ennis W; Kirsner R; O'Connell SM; Steinberg J; Falanga V
    Wound Repair Regen; 2006; 14(2):102-9. PubMed ID: 16630097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of living bilayered cell therapy (Apligraf) for heel ulcers.
    Karr J
    Adv Skin Wound Care; 2008 Jun; 21(6):270-4. PubMed ID: 18525250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apligraf in the treatment of neuropathic diabetic foot ulcers.
    Edmonds M;
    Int J Low Extrem Wounds; 2009 Mar; 8(1):11-8. PubMed ID: 19189997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
    Curran MP; Plosker GL
    BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf).
    Karr JC
    Adv Skin Wound Care; 2011 Mar; 24(3):119-25. PubMed ID: 21326023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study.
    Hu S; Kirsner RS; Falanga V; Phillips T; Eaglstein WH
    Wound Repair Regen; 2006; 14(4):427-33. PubMed ID: 16939570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Apligraf in the treatment of venous leg ulcers.
    Dolynchuk K; Hull P; Guenther L; Sibbald RG; Brassard A; Cooling M; Delorme L; Gulliver W; Bourassa DH; Ho V; Kunimoto B; Overholt T; Papp K; Tousignant J
    Ostomy Wound Manage; 1999 Jan; 45(1):34-43. PubMed ID: 10085970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Special segment: soft tissue matrices--Apligraf bilayered skin substitute to augment healing of chronic wounds in diabetic patients.
    DeCarbo WT
    Foot Ankle Spec; 2009 Dec; 2(6):299-302. PubMed ID: 20400430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue engineering in wound repair.
    Falanga VJ
    Adv Skin Wound Care; 2000; 13(2 Suppl):15-9. PubMed ID: 11074998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Wound healing in venous ulcers; mechanisms, approach and modern developments].
    Gibbs S; van den Hoogenband HM; de Boer EM
    Ned Tijdschr Geneeskd; 2007 Mar; 151(11):635-40. PubMed ID: 17441566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost.
    Zelen CM; Serena TE; Gould L; Le L; Carter MJ; Keller J; Li WW
    Int Wound J; 2016 Apr; 13(2):272-82. PubMed ID: 26695998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent.
    Trent JF; Kirsner RS
    Int J Clin Pract; 1998 Sep; 52(6):408-13. PubMed ID: 9894378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of Apligraf in acute wounds.
    Kirsner RS
    J Dermatol; 1998 Dec; 25(12):805-11. PubMed ID: 9990773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory, atypical lower extremity ulcers with tissue-engineered skin (Apligraf).
    Long RE; Falabella AF; Valencia I; Eaglstein WH; Kirsner RS
    Arch Dermatol; 2001 Dec; 137(12):1660-1. PubMed ID: 11735729
    [No Abstract]   [Full Text] [Related]  

  • 15. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers.
    Zelen CM; Gould L; Serena TE; Carter MJ; Keller J; Li WW
    Int Wound J; 2015 Dec; 12(6):724-32. PubMed ID: 25424146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers.
    Steinberg JS; Edmonds M; Hurley DP; King WN
    J Am Podiatr Med Assoc; 2010; 100(1):73-7. PubMed ID: 20093548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of ischemic wounds with noncontact, low-frequency ultrasound: the Mayo clinic experience, 2004-2006.
    Kavros SJ; Miller JL; Hanna SW
    Adv Skin Wound Care; 2007 Apr; 20(4):221-6. PubMed ID: 17415030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of bilayered living-cell therapy donor DNA 10 months after application: a case report.
    Serena TE; Bialas P
    Ostomy Wound Manage; 2009 Oct; 55(10):18-22. PubMed ID: 19864692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wound bed score and its correlation with healing of chronic wounds.
    Falanga V; Saap LJ; Ozonoff A
    Dermatol Ther; 2006; 19(6):383-90. PubMed ID: 17199681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apligraf--a living human skin equivalent for the treatment of chronic wounds.
    Streit M; Braathen LR
    Int J Artif Organs; 2000 Dec; 23(12):831-3. PubMed ID: 11197742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.